Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: A systematic review

Journal of Diabetes Science and Technology

Volumn 7, Issue 6, 2013, Pages 1595-1606

  Kerr, David ^a   Wizemann, Erik ^b   Senstius, Jakob ^c   Zacho, Mette ^c   Ampudia Blasco, Francisco Javier ^d  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b Diabetes Schwerpunktpraxis   (Germany)

^c NOVO NORDISK A S   (Denmark)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Diabetes mellitus; Insulin pump; Protein stability; Rapid acting insulin

Indexed keywords

INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; META CRESOL; PRESERVATIVE;

AGITATION; CATHETER; CATHETER OCCLUSION; CLINICAL STUDY; CONTINUOUS INFUSION; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; DRUG STABILITY; EVIDENCE BASED PRACTICE; GLYCEMIC CONTROL; HIGH TEMPERATURE; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MEDICAL LITERATURE; MOLECULAR WEIGHT; PH; PROTEIN CONTENT; REVIEW; RISK FACTOR; SKIN TEMPERATURE; SYSTEMATIC REVIEW;

AMINO ACID SEQUENCE; DIABETES MELLITUS, TYPE 1; DRUG STABILITY; HUMANS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN ASPART; INSULIN INFUSION SYSTEMS; INSULIN LISPRO; INSULIN, SHORT-ACTING; MOLECULAR SEQUENCE DATA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84900530439     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700620     Document Type: Review

References (33)

1. Pickup J. Insulin pumps. Int J Clin Pract Suppl. 2011;170:16-9.
2. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;2:CD003287.
3. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42(10):1151-67.
4. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46(2):265-70.
5. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38(6):429-33.
6. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analoguesaspart, lispro, and glulisine. Endocr Pract. 2011;17(2):271-80.
7. Nielsen L, Frokjaer S, Brange J, Uversky VN, Fink AL. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry. 2001;40(28):8397-409.
8. Van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):607-14.
9. Phillips BD, Aurand LA, Bedwell MM, Levy JR. A novel approach to preventing diabetic ketoacidosis in a patient treated with an insulin pump. Diabetes Care. 2003;26(10):2960-1.
10. Woods RJ, Alarcón J, McVey E, Pettis RJ. Intrinsic fibrillation of fast-acting insulin analogs. J Diabetes Sci Technol. 2012;6(2):265-76.
11. Naik S, Kerr D, Begley J, Morton J. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study. Diabetes Technol Ther. 2012;14(11):1018-22.
12. Ling J, Hu M, Hagerup T, Campbell RK. Lispro insulin: adsorption and stability in selected intravenous devices. Diabetes Educ. 1999;25(2):237-45.
13. Jars MU, Hvass A, Waaben D. Insulin aspart (AspB28 human insulin) derivatives formed in pharmaceutical solutions. Pharm Res. 2002;19(5):621-8.
14. Jorgensen L, Bennedsen P, Hofmann SV, Krogh RL, Pinholt C, Groenning M, Hostrup S, Bukrinsky JT. Adsorption of insulin with varying self-association profiles to a solid Teflon surface--influence on protein structure, fibrillation tendency and thermal stability. Eur J Pharm Sci. 2011;42(5):509-16.
15. DeFelippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006;8(3):358-68.
16. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM, Frank BH. Stability of insulin lispro in insulin infusion systems. Diabetes Care. 1997;20(7):1061-5.
17. Sharrow SD, Glass LC, Dobbins MA. 14-day in vitro chemical stability of insulin lispro in the minimed paradigm pump. Diabetes Technol Ther. 2012;14(3):264-70.
18. Senstius J, Harboe E, Westermann H. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump. Diabetes Technol Ther. 2007;9(1):75-9.
19. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007;9(6):517-21.
20. Senesh G, Bushi D, Neta A, Yodfat O. Compatibility of insulin lispro, aspart, and glulisine with the Solo micropump, a novel miniature insulin pump. J Diabetes Sci Technol. 2010;4(1):104-10.
21. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2005;7(1):142-50.
22. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2007;9(1):26-35.
23. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2008;2(3):450-5.
24. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001;24(1):69-72.
25. Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F. A comparison of insulin lispro and bufered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications. 2001;15(6):295-300.
26. Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care. 1999;22(5):784-8.
27. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-44.
28. Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E, Miselli V, Brandolini S, Fabbri T, Meandri P, Cannatà F. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. 2008;10(6):495-8.
29. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31(2):210-5.
30. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 2002;111(5):69-77.
31. Eli Lilly and Company Limited. Humalog summary of product characteristics. 2012. http://www.medicines.org.uk/emc/medicine/9314. Accessed December 7, 2012.
32. Novo Nordisk Limited. NovoRapid summary of product characteristics. http://www.medicines.org.uk/emc/medicine/25033/SPC. Accessed December 7, 2012.
33. Sanofi. Apidra summary of product characteristics. http://www.medicines. org.uk/EMC/medicine/26476/SPC. Accessed December 7, 2012.